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Abstract The clinical use of in vivo magnetic resonance
spectroscopy (MRS) has been limited for a long time,
mainly due to its low sensitivity. However, with the
advent of clinical MR systems with higher magnetic ﬁeld
strengths such as 3 Tesla, the development of better coils,
and the design of optimized radio-frequency pulses,
sensitivity has been considerably improved. Therefore, in
vivo MRS has become a technique that is routinely used
more and more in the clinic. In this review, the basic
m e t h o d o l o g yo fi nv i v oM RS is described—mainly
focused on
1H MRS of the brain—with attention to
hardware requirements, patient safety, acquisition meth-
ods, data post-processing, and quantiﬁcation. Further-
more, examples of clinical applications of in vivo brain
MRS in two interesting ﬁelds are described. First, toge-
ther with a description of the major resonances present in
brain MR spectra, several examples are presented of
deviations from the normal spectral pattern associated
with inborn errors of metabolism. Second, through
examples of MR spectra of brain tumors, it is shown that
MRS can play an important role in oncology.
Keywords Magnetic resonance spectroscopy 
Human  Methodology  Inborn error  Metabolism 
Brain tumor
Abbreviations
1D, 2D, 3D One-, two-, three-dimensional
Acq Acquisition
Ala Alanine
CHESS Chemical shift—selective water suppression
Cho Choline
Cre Creatine
CSD Chemical shift displacement
CSI Chemical shift imaging
ECC Eddy current correction
FOV Field of view
FT Fourier transformation
GABA c-Aminobutyric acid
Gln Glutamine
Glu Glutamate
Glx Glutamine ? glutamate
Gly Glycine
Ins Myo-inositol
jMRUI Java-based magnetic resonance user
interface
Lac Lactate
Lip Lipid
LCModel Linear combination of model spectra
MM Macromolecules
MR Magnetic resonance
MRI Magnetic resonance imaging
MRS Magnetic resonance spectroscopy
MRSI Magnetic resonance spectroscopic imaging
NAA N-acetyl aspartate
NAAG N-acetylaspartyl glutamate
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PRESS Point-resolved spectroscopy
RF Radio frequency
SAR Speciﬁc absorption rate
SNR Signal-to-noise ratio
STEAM Stimulated echo acquisition mode
SVS Single voxel spectroscopy
Tau Time delay in PRESS
T Tesla
TE Echo time
TM Mixing time
TR Repetition time
VOI Volume of interest
WET Water suppression enhanced through T1
effects
Introduction
Nuclear magnetic resonance (NMR) spectroscopy is
generally known as an analytical method in chemistry to
identify molecules and to determine their biophysical
characteristics. The main application of nuclear magnetic
resonance in the clinic is, without a doubt, to obtain
detailed anatomical images non-invasively throughout the
human body by magnetic resonance imaging (MRI).
However, not only MRI but also NMR spectroscopy has
several clinical and biomedical applications. When an
NMR technique is used in vivo and in particular in the
clinic, the convention is to leave the term ‘‘nuclear’’ out of
the name as inclusion of this part may erroneously lead to
associations with nuclear medicine, radioactive materials,
and ionizing radiation. Therefore, in vivo NMR spec-
troscopy is referred to as magnetic resonance spectros-
copy (MRS). Just as in its application in chemistry, MRS
allows the detection of relatively small molecules, typi-
cally in concentrations of 0.5–10 mM, with sufﬁciently
high ﬂexibility within cells or in extra-cellular spaces. The
obtained MR spectra supply information on metabolic
pathways and changes therein, which makes MRS a very
suitable technique to monitor metabolic changes due to
disease and to follow treatment. In this review an over-
view is presented on in vivo MRS methodology and some
biomedical and clinical applications, by which persons
familiar with the chemical application of NMR spectros-
copy may learn about its application in the clinic. Most
emphasis is laid on
1H MRS of the human brain, which is
the main clinical MRS application. As it is impossible to
give a complete description of all biomedical applications
of in vivo MRS, this review is limited to examples of
human brain MRS in the identiﬁcation of inborn errors
in metabolism, and diagnostics and research in brain
cancer.
In vivo MRS methodology
Basic requirements
MR spectra can be obtained of several metabolites in
the human body by using various nuclei, such as
1H,
31P,
19F,
13C,
23Na, which all can provide valuable metabolic
and physiological information. In biomedicine, however,
mainly
1H MRS is used because of the high sensitivity of
the
1H nucleus, the almost 100% availability of this iso-
tope, and the abundant presence of this nucleus in most
metabolites. In addition,
1H MRS can be performed rela-
tively easily using clinical MR imaging systems with
standard radio-frequency (RF) coils developed for the
acquisition of diagnostic MR images. In fact, the MR
signal of the
1H nuclei in water and fat is used to obtain
MR images. Common clinical MR systems have magnetic
ﬁeld strengths between 0.2 and 3 Tesla (T). In MRS
applications, it is generally not the signals of water and fat
that are of interest, but rather the smaller metabolite sig-
nals, thus a magnetic ﬁeld of sufﬁcient strength is required.
Therefore, most clinical MRS measurements are performed
using MR systems with ﬁeld strengths of 1.5 T or higher.
In particular, the advent of clinical MR systems with a ﬁeld
strength of 3 T has improved signal-to-noise ratio (SNR) in
MR spectra, creating the possibility of obtaining spectra
from smaller volumes.
In the last few years, human MR systems with much
higher ﬁeld strengths of 7 and 9.4 T have been installed,
and NeuroSpin in Saclay (France) even has plans for an
11.7 T MR system to become available for human appli-
cations in 2011. At the moment, however, such MR sys-
tems with ultra high ﬁelds are only used for scientiﬁc
research and their clinical usefulness is still under debate
because of very high costs, several technical challenges,
and concerns about biological effects (Hennig 2008). In
addition to the main magnet to create a strong static
magnetic ﬁeld (B0), gradient coils are used to generate
magnetic ﬁeld gradients in three directions (Gx,G y, and
Gz); these are necessary for selection of the volume of
interest (VOI) from which the MRS signal is obtained.
These ﬁeld gradients are in the range of 10–50 mT/m with
a switching time on the order of a millisecond.
For
1H MRS, the RF body coil built inside the magnet
bore may be used as an RF transmitter in combination
with another coil positioned on the surface or around the
body for RF signal reception (Fig. 1). Another possibility
is the use of a transmit-receive coil, which is used for
both transmission and reception. In recent years, many
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123improvements in MR coil design have been made, for
example the development of various phased-array coil
designs, which has resulted in improved sensitivity (Fujita
2007). A small surface coil yields a higher SNR closer to
the coil surface than a volume coil, but the sensitive region
is much smaller. Through the combination of multiple
surface coils in a phased-array coil concept, high SNR can
be combined with an extended ﬁeld of view (FOV). For
MRS using nuclei other than
1H, the standard MRI coils
can not be used, but special coils tuned to the desired
nucleus have to be bought or built. Often these coils consist
of multiple coils, one tuned to the desired nucleus such as
31Po r
13C and another tuned to
1H to allow decoupling or
polarization transfer.
For all MR examinations, both MRI and MRS, some
safety precautions have to be taken against potential risks
caused by the main magnetic ﬁeld, the switching of the
magnetic ﬁeld gradients, or the RF radiation. No harmful
physiological effects are known to be caused by the main
magnetic ﬁeld of clinical MR systems of 1.5–3 T, but the
strong magnetic ﬁeld does attract ferromagnetic objects. It
should be determined if the patient has an implanted
electronic device such as a pacemaker or an internal deﬁ-
brillator or other magnetic material such as cochlear
implants or ferromagnetic aneurysm clips. Also the pres-
ence of metal splinters at critical locations, e.g. in the eye
or in the brain is a contra-indication for an MR investiga-
tion. And even a clinician entering the room with loose
metal objects such as a pen or a pair of scissors in his
pocket may become a danger for a patient lying in the
magnet, as these objects can be launched in the direction of
the patient by the strong magnetic ﬁeld. In addition,
watches and credit cards should be left outside the room as
these may be damaged by the magnetic ﬁeld.
The switching of the magnetic ﬁeld gradients produces
an acoustic noise for which the patients should wear ear
protection. In addition, fast gradient switching may induce
nerve stimulation, but such fast switching is not often
applied in MRS, and on clinical scanners the gradients used
are monitored and a warning appears if gradient switching
becomes too fast. The ﬁnal effect may be slight heating
(\1–2C) of the patient by RF radiation. The amount of
energy absorbed per mass of tissue, deﬁned as speciﬁc
absorption rate (SAR), is also monitored and strictly lim-
ited on clinical MR systems. One contra-indication not
related to safety is claustrophobia. Patients with severe
claustrophobia and also patients who cannot lie down
without movement such as young children may be sedated
or anesthetized to undergo an MR investigation.
MRS data acquisition
Generally an MRS examination starts with the acquisition
of some anatomical MR images of the organ of interest.
Then, these MR images are used as a guide to select a
volume of tissue from which the MR spectrum will be
acquired. In single voxel spectroscopy (SVS), this can be a
single volume positioned in a tumor or in a particular
location where metabolism may be disturbed due to the
disease of the patient. Another possibility is magnetic
resonance spectroscopic imaging (MRSI), originally
introduced as chemical shift imaging (CSI; Brown et al.
1982), in which a large volume is divided in multiple
smaller voxels, with each giving rise to a spectrum
simultaneously. This technique, a sort of hybrid of MRS
and MRI, is suitable for the detection of spatial distribu-
tions, e.g., to determine the region affected by tumor
inﬁltrations. In
1H MRS, techniques such as chemical shift-
selective water suppression (CHESS; Haase et al. 1985)o r
water suppression enhanced through T1 effects (WET; Ogg
et al. 1994) are usually used to suppress the water signal
when metabolite spectra are acquired. In addition, a spec-
trum without water suppression is obtained, which can be
used for line-shape corrections and quantiﬁcation.
The predominant SVS techniques used for acquisition of
1H MR spectra, mostly applied to the brain, are known as
point-resolved spectroscopy (PRESS; Ordidge et al. 1985;
Bottomley 1987) and stimulated echo acquisition mode
(STEAM; Frahm et al. 1989). The main difference between
STEAM and PRESS is the acquisition of a stimulated echo
obtained by three 90 pulses in STEAM and a second echo
obtained by a 90 excitation pulse followed by two 180
refocusing pulses in PRESS (see Fig. 2). In both methods,
each of the three pulses is combined with a gradient in X, Y,
or Z direction used to select a slice in that direction. Only
the signal of the rectangular volume (single voxel) in which
all three slices overlap is refocused and acquired. By
Fig. 1 Pediatric patient positioned in the headcoil on the table of the
MR system just before the table with patient and coil is moved into
the magnetic bore for the MR investigation
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123changing the delay times between the pulses, the echo time
(TE) can be altered. When a longer TE is used, the signal
will be decreased due to T2 relaxation, and the phase of
multiplet signals is changed due to J-coupling. For quan-
titative measurements, the combination of a short echo
time and a long repetition time (TR) is generally used to
obtain signals with minimal signal loss due to T2- and T1-
weighting (Fig. 3, upper row). Longer TE measurements
are used to obtain spectra with only a limited number of
sharp (often singlet) resonances, which are relatively easy
to analyze (Fig. 3, bottom row). Often a TE of 135–144 ms
is used, as this results in a spectrum in which the doublet
signal of lactate with a J-coupling constant of approxi-
mately 7 Hz is completely inverted (see Fig. 6 below).
An important difference between the two SVS pulse
sequences is that, by acquisition of a stimulated echo in
STEAM, half of the signal is not used resulting in a 50%
lower SNR compared with PRESS. The disadvantage of
PRESS volume selection has long been the use of two 180
pulses. As the maximum pulse intensity is limited, the
pulse length of a 180 pulse is generally longer than the 90
pulse or the shape of the pulse is adapted to limit its length.
Therefore, the presence of these two 180 pulses does not
allow very short TE, they result in a less optimal slice
selection proﬁle, and their bandwidth is smaller, giving rise
to a larger chemical shift displacement (CSD) artifact. This
CSD artifact arises from the fact that signals with different
chemical shifts experience different (frequency-encoded)
slice selections and thus do not originate from exactly the
same volume. This effect becomes larger at higher mag-
netic ﬁeld strengths. For these reasons, STEAM is the
method of choice for data acquisition with short TE and
precise volume selection. Lately, however, the character-
istics of the 180 pulses used in PRESS have been more
and more improved, e.g. by numerical optimization
(Schulte et al. 2008) or replacement of each 180 pulse by
two adiabatic pulses (Scheenen et al. 2008). These devel-
opments, together with the very important factor of a
doubled SNR compared with STEAM, have made the
PRESS sequence the most popular SVS sequence for
1H
MRS currently.
In MRSI, phase-encoding gradients are used in one,
two, or three dimensions (1D, 2D, 3D) to sample k-space
(Skoch et al. 2008) for volume selection in a similar way
as in MRI, but with larger volume elements (voxels).
Generally these phase-encoding gradients are applied after
RF
° 0 8 1 ° 0 9 180°
tau TE/2 TE/2 - tau
Acq
PRESS
STEAM RF
90°
TE/2 TM TE/2 
Acq
90° 90°
Fig. 2 Schematic overview of the pulse sequences PRESS and
STEAM. It should be noted that each of the three RF pulses is
combined with a gradient in three different directions (X, Y, and Z)t o
allow selection of a rectangular volume. RF Radio frequency, tau
time delay between 90 and 180 pulses in PRESS, TE echo time,
TM mixing time
1.0 3.0 2.0
ppm
4.0
NAA
Cre
Cho
Cre
Ins
Glx
MM
1.0 3.0 2.0
ppm
4.0
Cre
Cho
NAA
Cre Cho
Cre
Cre
Ins Glx
MM
NAA
NAA
Cre
Cho Cre
TE = 
20 ms
TE = 
136 ms
Parietal
white matter
Occipital
gray matter
Fig. 3 Single-voxel MR
spectra obtained at a ﬁeld
strength of 3T from white
matter (left) and gray matter
(right) from a healthy volunteer.
The voxel positions are
indicated in the corresponding
MR images. Spectra were
obtained with PRESS volume
selection (TE/TR = 20/
5,000 ms for upper row and TE/
TR = 136/2,000 ms for lower
row). The most prominent
signals are labeled: Cre
creatine, Ins myo-inositol, Cho
choline, Glx glutamine and
glutamate, NAA N-acetyl
aspartate, MM macromolecules.
Note the difference in relative
signal intensities of Cho and Cre
in white and gray matter, for
which the labels are indicated in
blue
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123an excitation pulse in combination with a gradient for
slice selection or with volume pre-selection in which a
volume of interest selected by STEAM or PRESS is
further subdivided into smaller voxels. In MRSI, spectra
of all voxels are acquired simultaneously, and spatial
distributions of various metabolites can be obtained in a
single experiment (see Fig. 4). In contrary to the ﬁxed
voxel position in SVS, voxels obtained by phase encoding
can be repositioned during post processing by grid
shifting. The time needed to perform a classical MRSI
experiment is at least equal to the number of phase-
encoding steps multiplied by the TR. This means that the
acquisition time is not larger than it is for SVS if the
number of phase-encoding steps is equal to the number of
averages required to obtain sufﬁcient SNR. However, for
signals with high intensity, the number of steps needed
for spatial encoding in classical MRSI may be larger than
the number of averages required for an acceptable SNR.
To solve this time problem, only the phase-encoding steps
that lead to sampling of the most important points in
k-space inside the central circle (2D) or sphere (3D) can
be used (Maudsley et al. 1994). Another possibility is to
acquire multiple echoes with each echo encoding for a
different point in k-space in so-called turbo spectroscopic
imaging (Duyn and Moonen 1993) or to use the delay TR
to measure a data point for another slice in multislice
MRSI (Duyn et al. 1993). More recently, other fast MRSI
techniques have been developed in which varying gradi-
ent strengths during the data acquisition period are used
for spatial encoding (Posse et al. 1994)o ri nw h i c hm o r e
recently developed parallel spectroscopic imaging tech-
niques are implemented (Dydak et al. 2001). In particular,
3D applications of MRSI beneﬁt from these accelerating
modiﬁcations.
The main disadvantage of MRSI is the presence of so-
called voxel bleed, which means that the spectrum of a
voxel may be contaminated by signals originating from
adjacent voxels with both positive and negative intensities
due to the shape of the point spread function associated
with the limited matrix size used in MRSI (Brown 1992).
The effect of voxel bleed can be reduced by the use of
special ﬁlters before Fourier transformation (FT) in the
spatial domain, but this increases the dimensions of the
voxels. Generally, SVS is used when accurate quantiﬁca-
tion is desirable, and MRSI is used to obtain information on
spatial distributions.
Cho
Cre
NAA
Lac
Cho/NAA
B A
D C
Fig. 4a–d Magnetic resonance
spectroscopic imaging (MRSI)
data obtained from a patient
with a brain tumor (low-grade
oligodendroglioma). a MR
image with volume of interest
selected by STEAM in white
and two-dimensional MRSI grid
in blue. Spectra are only
acquired from the MRSI voxels
inside the volume of interest.
The dotted line in a indicates
the MRSI voxels shown in b.
b Part of the spectral image
showing MRSI voxels with their
corresponding spectra.
c Enlargement of the spectrum
obtained from the voxel
indicated in red in b and c. The
spectrum (TE = 20 ms) shows
a typical pattern for a low-grade
brain tumor with increased
choline, decreased NAA, and
the doublet of lactate.
d Metabolite map showing the
intensity distribution of the ratio
of choline to NAA over the
volume of interest with the
highest intensity indicated in
red at the position of the tumor
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Common post-processing of SVS spectra (in ‘t Zandt et al.
2001) includes multiplication with a ﬁlter in the time
domain, zero-ﬁlling, FT, phasing, and baseline correction,
which is basically not different from post-processing of
high-resolution NMR data. In localized MRS, however,
gradient switching may cause eddy current artifacts that are
time and space dependent. Such artifacts in a metabolite
spectrum can be removed with a reference water signal
obtained without water suppression using the same
sequence and from the same VOI. The method most
commonly applied consists of a point-wise division in the
time domain by the phase of the water signal at that par-
ticular time point (Klose 1990). This so-called eddy current
correction (ECC) is applied as a ﬁrst post-processing step,
and it results in line-shape corrections in the metabolite
spectrum together with the removal of offsets in zero-order
phasing and frequency. Although eddy currents are smaller
in modern MR systems making line-shape correction less
essential, ECC correction is still commonly used for
automatic phasing and frequency offset correction. In
MRSI, the data are ﬁrst multiplied with a ﬁlter (often
Hamming or Hanning) followed by FT in the spatial
domain. Thereafter, the time-domain data associated with
each voxel are processed identically as SVS data to MR
spectra. The spectra obtained from each voxel and their
spatial origin can be shown in a spectral map (Fig. 4b).
After the intensities of a certain metabolite signal in all
spectra are quantiﬁed (see below), MRSI offers the possi-
bility to construct a metabolite map in which the spatial
distribution of the speciﬁc metabolite or a metabolite ratio
is shown (Fig. 4d).
For quantiﬁcation the integrals of the resonances present
in the spectrum have to be determined. Presently two main
approaches are followed using analyses in the frequency
domain or in the time domain. Although on most MR
systems, software programs are available to integrate the
signals present in the MR spectrum or to ﬁt them to model
functions in order to obtain quantitative results, often
software programs with more advanced algorithms are
applied. A widely used software package for quantiﬁcation
is LCModel (linear combination of model spectra; Prov-
encher 1993), in which frequency domain data are ﬁtted to
model spectra in a database resulting in intensity estimates
of each metabolite. The model spectra in the database may
be obtained from in vitro measurements of metabolite
solutions using the same pulse sequence and timings as the
in vivo measurement or by computer simulations. The
advantage of the LCModel program is that the entire
spectral pattern associated with each metabolite is used for
the ﬁtting. Therefore, the software package is very popular
for the evaluation of
1H MR spectra of the brain obtained
with a short TE, which show many—often overlapping—
resonance lines (Fig. 3, upper row).
For spectra with fewer (overlapping) lines, such as
31P
MR spectra or
1H MR spectra obtained with long TE
(Fig. 3, lower row), the program jMRUI (Java-based
magnetic resonance user interface; http://www.mrui.uab.
es/mrui/) is generally used. In jMRUI, the data are ﬁtted in
the time domain using prior knowledge of frequencies,
linewidths, coupling patterns, etc. By using time-domain
ﬁtting, uncertainties introduced by the shape of the baseline
are avoided. In addition, the program offers the possibility
to remove unwanted signals such as the water signal. Both
software packages, LCModel and jMRUI, not only provide
estimates on signal intensities but also give information on
the quality of the ﬁt with the Crame ´r-Rao lower bound as
an error estimation (Cavassila et al. 2001).
The quantiﬁcation methods described above result in
signal intensities in arbitrary units, with ratios often used in
clinical diagnosis. For brain spectra, the intensity of the
methyl resonance of creatine is commonly used for nor-
malization. Although this normalization removes differ-
ences, for example in volume and coil loading, a change
in a ratio can be caused by changes in both numerator
and denominator (Li et al. 2003). Therefore, for absolute
quantiﬁcation, referencing to an internal or external refer-
ence signal is necessary. The water signal obtained from
the same volume is frequently used as an internal reference
(e.g., Soher et al. 1996), but in this case a particular water
content has to be assumed, which may be changed in
pathology. When an external reference is used, the signals
measured in vivo are correlated to the signal intensity of a
compound with a known concentration in an external
phantom, which can be present inside the coil at the time of
the in vivo examination or which may be placed at the
position of the patient afterwards. If a phantom replace-
ment is used, the coil loading may be different from the
situation in which the patient is measured, which affects
signal intensity (Hoult and Richards 1976). For that reason,
the signal intensity is corrected for coil loading differences
using the reciprocity principle (Michaelis et al. 1993). For
absolute quantiﬁcation, it is best to acquire spectra with
minimal T1- and T2-weighting by using a long TR and
short TE, as each metabolite line has its own values for T1
and T2 relaxation, which makes it difﬁcult to correct for
relaxation effects.
The use of absolute quantiﬁcation should in principle
lead to metabolite tissue levels whose values can be com-
pared among institutes, independent of the exact mea-
surement method used. In practice, however, variations in
data acquisition, post-processing, and quantiﬁcation result
in small differences, and metabolite values obtained from a
patient can be best compared with a reference data set of
‘‘institutional units’’ obtained on healthy volunteers using
532 Eur Biophys J (2010) 39:527–540
123entirely identical procedures in the same institute. In this
reference data set, the location of the VOI has to be taken
into account, since the metabolic content and thus the
spectrum deviate between gray and white matter in the
brain (Fig. 3). And also the location within gray or white
matter is of inﬂuence due to regional variations in metab-
olite concentrations; for instance the choline content of
frontal gray matter is approximately 50% larger than that in
occipital gray matter (Pouwels and Frahm 1998). Finally,
patient age is important as metabolite concentration in the
brain changes, both in children up to the age of ten years
(Kreis et al. 1993; Pouwels et al. 1999) and in elderly
people (Gruber et al. 2008).
Clinical applications
Normal brain and metabolic disorders
Estimations of the number of metabolites present in the
human body range between 2,000 and 20,000 (Schmidt
2004). In patients with an inborn error in metabolism, the
concentration of any of these metabolites may be
u n u s u a l l yh i g ho rl o wd u et oa ni n h e r i t e dd e f e c ti n
enzymatic activity. MRS is an ideal technique to measure
changes in metabolite levels non-invasively, and thus the
technique is very suitable in the diagnostics of metabolic
disorders. However, it should be noted that only small
metabolites with sufﬁciently high concentration can be
observed by MRS. In addition, pattern changes in the
MR spectrum may only be indicative of a general
pathology such as demyelination in white matter or
ischemia and not speciﬁc enough to identify a metabolic
disorder. Still, such general pattern changes in combi-
nation with other clinical and biochemical information
may help to ﬁnd the correct diagnosis. In a recent review,
Cecil showed brain
1H MR spectra of many metabolic
diseases, including lysosomal disorders, peroxisomal dis-
orders, mitochondrial disorders, white-matter disorders,
disorders of amino and organic acid metabolism, and
some miscellaneous disorders (Cecil 2006). However,
many of the spectra presented are not unique for the
corresponding disease. Below, based upon the major
resonances visible in the MR spectrum, examples are
described in which the MR spectrum plays an important
role in the identiﬁcation of the disorder and the increase,
decrease, presence, or absence of a resonance may be
pathognomonic.
In
1H MR spectra of the brain (Fig. 3), the most
prominent signals are generally assigned as N-acetyl
aspartate (NAA), creatine (Cre), and choline (Cho). In fact,
each of these peaks arises from a number of compounds.
The NAA signal at 2.01 ppm mainly originates from
the methyl group of N-acetyl aspartate but has some contri-
bution of N-acetylaspartyl glutamate (NAAG; 2.04 ppm).
The creatine peaks at 3.03 ppm (methyl protons) and
3.91 ppm (methylene protons) represent both creatine and
phosphocreatine, and the choline resonance at 3.21 ppm
contains signals from the three methyl groups of free choline
(3.19 ppm), and in particular from the choline moieties
present in glycerophosphoryl choline (3.21 ppm) and phos-
phocholine (3.21 ppm).
NAA is generally considered to be a neuronal marker,
which is synthesized in the mitochondria of the neuron and
transported along axons, but it has also been suggested to
play a role as a cerebral osmolyte (Baslow 2002). The
concentration of NAA is reduced in case of neuronal loss
as in many white-matter diseases and also in brain tumors
(see next section). One case of a child without NAA and
NAAG in its brain MR spectrum has been reported (Martin
et al. 2001); this complete absence is most likely due to a
defect of the anabolic enzyme L-aspartate N-acetyltrans-
ferase. The opposite phenomenon—signiﬁcant increase of
the NAA resonance—is very speciﬁc for Canavan disease,
which belongs to the group of neurotransmitter diseases
(Fig. 5). Because of a deﬁciency in the enzyme aspar-
toacylase, NAA accumulates in the mitochondria and
impairs myelin synthesis resulting in this severe white-
matter disease (Janson et al. 2006). In Salla disease, the
Canavan
control
1.0 3.0 2.0
ppm
NAA
Cre Cho
Fig. 5 MR spectra obtained at 1.5 T (TE/TR = 135/2,000 ms) of
parietal white matter of a 13-month-old patient with Canavan disease
(upper row) and an age-matched control (lower row). Note the
remarkable increase in NAA signal in the spectrum of the patient,
together with decreases in choline and creatine
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raminic acid, but the increase in the NAA resonance is not
so prominent, probably due to a concomitant decrease in
N-acetyl aspartate (Varho et al. 1999).
Creatine and phosphocreatine are involved in energy
metabolism, and their concentration is quite constant.
Therefore, they are often used in the calculation of
metabolite ratios. However, regional differences exist and
also pathologies such as a tumor may reduce the Cre signal
intensity. In contrast, gliosis in white matter may slightly
increase the signal. Complete absence of the Cre signal
points directly to a defect in creatine synthesis, as in gua-
nidino acetate methyltransferase deﬁciency (Sto ¨ckler et al.
1994) or in L-arginine glycine amidinotransferase deﬁ-
ciency (Item et al. 2001), or to a creatine transporter defect
(Cecil et al. 2001). It should be noted that a low Cre signal
originating from food may occur in the brain of patients
with a defect in Cre synthesis, although the increase in Cre
concentration upon Cre supplementation is slow, and the
concentration may still not be normalized after 2 years
(Sto ¨ckler et al. 1996).
Choline and choline-containing compounds play an
important role in membrane synthesis and an increase in
the Cho signal is indicative of an increased membrane
turnover. In tumors the choline signal is correlated with
malignancy. However, in cerebral infarction and inﬂam-
mation the Cho signal may also increase, which may
hamper correct differentiation between tumors and other
pathologies. No speciﬁc metabolic defects have been
described so far in which the intensity of the choline peak
may be decisive in the diagnosis.
In MR spectra obtained with short echo time, another
prominent signal is visible at 3.6 ppm, which mainly orig-
inates from two protons of myo-inositol (Ins, 3.61 ppm) and
also has a contribution of the singlet of glycine (Gly,
3.55 ppm). In particular in spectra obtained at a ﬁeld
strengthof 1.5 T, the pseudo-singlet of Ins and the singlet of
Gly are difﬁcult to separate, but in spectra obtained at 3.0 T,
the multiplet pattern of Ins is different and separation is
feasible even at short echo time. Ins is a simple sugar that is
primarily synthesized in glial cells and that is considered to
be a glial marker and an osmolyte. The concentration of Ins
increases with glial proliferation or with glial cell-size
increase, both of which occur in inﬂammation. In addition,
Ins may represent a breakdown product of myelin.
Increased Ins is present in gliosis, astrocytosis, and in dis-
orders such as Alzheimer disease, and its increase is not
very speciﬁc. The signal of Gly present at almost the same
chemical shift position has a longer transversal relaxation
time, T2, so that it is also present in MR spectra obtained
at longer echo times (e.g., 136 ms). Glycine is an amino
acid, and a prominent increase in its concentration and
its resonance peak has been observed in non-ketotic
hyperglycinemia originating from a defect in the glycine
cleavage system (Heindel et al. 1993).
The doublet signal of the methyl group of lactate (Lac;
center at 1.31 ppm), with its normal concentration of
approximately 0.5 mM, is not or hardly visible in brain MR
spectra. However, under anaerobic conditions its concen-
tration increases and the lactate signal appears as a doublet
with positive sign in spectra obtained with short echo times
and as an inverted doublet in spectra obtained with a TE of
136 ms (see Fig. 6). Increased lactate signals occur when
the normal aerobic oxidation mechanism fails and anaer-
obic glycolysis becomes more important, which may occur
in many pathologies, such as hypoxia and ischemia, brain
tumors, and metabolic defects, in particular mitochondrial
disorders. In the brain of patients with a mitochondrial
disorder, an increase in lactate signal can often be
observed, in particular in spectra obtained from the basal
ganglia (Fig. 6). The signal of the methyl group of the
amino acid Alanine (Ala; center at 1.47 ppm) behaves
similarly to the signal of Lac, with a positive sign at short
TE and an inverted doublet at a TE of 136 ms. Ala can—
just as Lac—be formed from pyruvate when the normal
route of pyruvate into the Krebs cycle is disturbed.
Increased levels of Ala can be found in defects in oxidative
ppm
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B
Fig. 6a, b MR spectra obtained at 3T of basal ganglia (voxel
indicated on MR image) of a patient with Leigh syndrome, a
mitochondrial disorder. Spectra were obtained with PRESS volume
selection (TE/TR = 20/5,000 ms for a and TE/TR = 136/2,000 ms
for b). In a increased lactate is present as a positive doublet at
1.3 ppm on top of the broad signal of macromolecules. In spectrum b,
obtained with a longer TE of 136 ms, the broad signal of macromol-
ecules is not present, and the lactate doublet is inverted
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123metabolism, and in tumors it is speciﬁc for meningiomas
(Yue et al. 2008).
The last resonances that may appear with relatively high
intensity in a brain proton MR spectrum originate from
the methylene protons (1.3 ppm) and methyl protons
(0.9 ppm) of lipids. In normal healthy brain, these peaks
are absent, although inappropriate volume selection may
result in contamination of the spectrum with lipid signals
from tissue close to the skull. Lipid signals in pathology are
generally associated with necrosis such as in high-grade
brain tumors or metastases. In addition, lipid signals have
been observed in brain MR spectra of patients with mul-
tiple sclerosis (Wolinsky et al. 1990), Niemann-Pick dis-
ease type C (a lipid storage disorder; Sylvain et al. 1994),
and patients suffering from peroxisomal disorders affect-
ing lipid metabolism such as Zellweger syndrome and
Refsum’s disease (Cecil 2006). Lipid signals of varying
intensity including very high peaks have been observed in
white matter of patients with Sjo ¨gren–Larsson syndrome
(Fig. 7), which is caused by a defect in fatty acid aldehyde
dehydrogenase (Willemsen et al. 2004). In contrast, no
increased lipid signal is present in the spectra of gray
matter in these patients. A metabolite map of the lipid
signal shows that this metabolite has its highest concen-
tration around the frontal and occipital trigones of the
ventricles (Fig. 7).
Further examples of intense resonances of otherwise
absent metabolites in the brain MR spectrum of patients
with metabolic defects include the occurrence of
high resonances of the polyols arabinitol and ribitol
(*3.75 ppm) in ribose-5-phosphate isomerase deﬁciency
(Van der Knaap et al. 1999) and the presence of a promi-
nent succinic acid resonance (2.39 ppm) in succinic acid
dehydrogenase or complex II deﬁciency (Brockmann et al.
2002).
The signals of most other metabolites are smaller than
those mentioned so far, often due to splitting of the signals
into multiplets. In normal brain MR spectra, multiplet
signals of glutamate (Glu) and glutamine (Gln) appear
in the spectral regions 2.2–2.4 ppm and 3.6–3.8 ppm. In
particular at 1.5 T, the resonances of these two metabolites
are difﬁcult to separate, and therefore the sum of these is
often referred to as Glx. Glutamate is an important neu-
rotransmitter, but glutamine seems to respond to disease
mostly with increased cerebral concentration, for example,
in Reyes syndrome, hepatic encephalopathy, and hypoxic
encephalopathy (Ross and Blu ¨ml 2001). Some examples
of increases in small MRS signals in inborn errors of
metabolism are the signal increases of 3-hydroxy isovaleric
acid (1.28 ppm) in 3-methylglutaconic aciduria type I
(Engelke et al. 2006), of phenylalanine (7.3–7.4 ppm) in
phenylketonuria (Pietz et al. 2003), and of the neuro-
transmitter c-aminobutyric acid (GABA; 1.8–2.3 ppm and
2.9–3.1 ppm) in 4-hydroxybutyric aciduria or succinic
semialdehyde dehydrogenase deﬁciency (Novotny et al.
2003). It should be noted that the increase in the very small
signals of GABA can only be demonstrated by a special
MRS editing technique.
For identiﬁcation of metabolic disorders,
1H MRS of the
brain is predominantly used, although other parts of the
body such as muscle can also be investigated or other
nuclei may be used. For example,
31P MRS can be used to
study disturbed high-energy phosphate metabolism (Argov
et al. 2000), and
13C MRS has been applied to uncover
hitherto unknown disorders of NAA synthesis, glutamate
neurotransmission, Krebs-cycle, and glycolysis (Ross et al.
2003; Blu ¨ml et al. 2001). In addition, several body ﬂuids
such as urine, plasma, and cerebral spinal ﬂuid of patients
B
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Fig. 7 MR spectra obtained at 3T (PRESS, TE/TR = 20/5,000 ms)
from white (a) and gray matter (b) of a patient with Sjo ¨gren–Larsson
syndrome. The spectrum of white matter clearly shows the presence
of an intense lipid signal, caused by a defect in the enzyme fatty
aldehyde dehydrogenase, while this resonance is absent in the
spectrum of gray matter. In addition, the white-matter spectrum
shows slightly increased signals of choline, creatine, and myo-
inositol, associated with myelin abnormalities. The metabolite map of
the lipid (top right) depicts its distribution with the highest intensities
in the periventricular regions around the posterior and frontal trigones
of the ventricles
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123suspected of an inborn error of metabolism may be ana-
lyzed in vitro by high-resolution NMR (Moolenaar et al.
2003), which offers the advantage of much higher sensi-
tivity and resolution. For an extensive overview of in vitro
1H-NMR spectroscopy of body ﬂuids together with some
examples of in vivo
1H MRS in inborn errors of metabo-
lism, the reader is referred to a recent handbook on this
subject (Engelke et al. 2007).
Brain tumors
Oncology is another ﬁeld in which MRS is more and more
used both in a research setting and in the clinic. As in
tumor growth metabolism changes dramatically, MRS can
add valuable information to that obtained by conventional
radiological techniques such as MRI. Generally, the reso-
nance of total choline (3.2 ppm) increases in tumors. This
elevation is mainly caused by an increased rate of mem-
brane synthesis in cancer cells, and the increase in the Cho
signal is mostly caused by an increase in phosphocholine
and glycerophosphoryl choline, compounds involved in
membrane synthesis and degradation. In oncology, MRS is
mostly used to diagnose and investigate tumors in brain
(Nelson et al. 2002; Howe et al. 2003), prostate (Heerschap
et al. 1997), and breast (Bolan et al. 2005); the application
in brain will be discussed in more detail below. Most brain
tumors belong to the group of gliomas that originate from
the glial cells in the brain. Gliomas can be classiﬁed by cell
type (e.g., originating from oligodendrocytes or from
astrocytes), by grade (low grade is relatively benign and
high grade is very malignant), and by location. An example
of a tumor that does not originate from glial cells is a
meningioma, which originates from the meninges. MRS
may play a role in diagnosis, biopsy guidance to reduce
misdiagnosis or sometimes even replacing a biopsy, plan-
ning of surgery or radiotherapy, and monitoring of treat-
ment response or tumor recurrence.
As mentioned above, brain tumors generally show an
increase in the Cho signal, and the Cho level is believed to
correlate directly with proliferative potential and malig-
nancy (Herminghaus et al. 2002). Therefore, an increase in
the total choline signal is often used in the diagnosis of a
brain tumor. However, care should be taken as an elevated
Cho signal may also appear in other pathologies, such as
inﬂammation, stroke, radiation necrosis, reactive gliosis,
and multiple sclerosis. In addition, the correlation between
malignancy and total choline signal is not straightforward
as high-grade gliomas such as glioblastoma multiforme
may be very heterogeneous containing regions with
necrosis resulting mainly in lipid signals and other regions
with highly proliferating cells with high choline signals
(Fig. 8).
In contrast to Cho, the signal of the neuronal marker
NAA is generally reduced in brain tumors, due to the fact
that most brain tumors are non-neuronal in origin. Also a
reduced NAA is not speciﬁc for brain tumors but may
occur in other pathologies such as stroke and multiple
sclerosis. As the signal intensity changes in Cho and NAA
appear in opposite directions in brain tumors, changes in
the ratio of these two (the choline-NAA index) are often
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Fig. 8a–c On the left,a nM R
image of a patient with a
glioblastoma multiforme
showing regions with enhanced
signal intensity after contrast
administration, which is
indicative of a defective blood–
brain barrier as is often present
in high-grade brain tumors. An
MRSI grid is superimposed on
the MR image with three voxel
positions labeled A–C, for
which the corresponding spectra
(acquired with TE = 20 ms) are
presented. The variety in the
spectral patterns is indicative of
the tissue heterogeneity inside
the brain tumor, from viable
tumor tissue with a high choline
signal (a) to necrotic tissue
represented by only a lipid
signal (c)
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123used to depict regions of abnormality in MRSI spectra of
brain tumors (Nelson et al. 2002; Fig. 4c).
The signal of creatine is often reduced in brain tumors as
a result of altered energy metabolism. Only in gliomatosis
cerebri, an uncommon type of glioma, might the creatine
signal be increased (Galanaud et al. 2003). Metabolites that
are useful in the characterization of brain tumors include
Ins and Glx. Myo-inositol is high in low-grade gliomas and
decreases when the tumor grade increases (Howe et al.
2003). The signal intensity of glutamine and glutamate
(Glx) can be used to distinguish between oligodendrogli-
oma (high Glx) and astrocytoma (lower Glx) (Rijpkema
et al. 2003). Glx is also high in meningioma, of which the
spectra may also show signals of alanine, which is very
speciﬁc for this tumor type (Howe et al. 2003). As men-
tioned before, lactate is caused by anaerobic metabolism,
and its signal often appears in spectra of brain tumors (see
Fig. 4c). However, the intensity of the lactate signals seems
not to correlate with tumor malignancy (Kugel et al. 1992).
Finally, signals of lipids and macromolecules are charac-
teristic of necrotic regions in very malignant tumors and
metastases (Howe et al. 2003; Opstad et al. 2004).
Increases in signals of lactate and lipids in time may
therefore indicate the conversion of a low-grade tumor into
a more malignant one.
MRS of brain tumors may consist of single-voxel MRS,
in which often one voxel is located in the lesion and
another at a similar position in the contra-lateral hemi-
sphere of the brain, allowing the spectral patterns of both
the lesion and healthy tissue to be compared. As brain
tumors are often heterogeneous, multivoxel MRSI can be
very helpful to assess the spatial distribution of the most
aggressive part of the tumor (Fig. 8). In addition, high-
grade tumors often inﬁltrate surrounding tissue; this only
becomes visible by MRSI showing spectra with abnormal
patterns outside the lesion with increased signal intensity in
contrast-enhanced MRI. Therefore, MRSI may also help to
distinguish between a high-grade glioma and a metastasis,
as the glioma generally shows inﬁltrations and a metastasis
is spatially restricted. In addition, the ratio between
lipid methylene signal intensity at 1.3 ppm and lipid
methyl signal intensity at 0.9 ppm has been shown to be
higher in metastases than in high-grade gliomas (Opstad
et al. 2004).
In Fig. 9a an example is shown of an MR spectrum with
a high lipid signal obtained from a brain lesion of a patient
who had been treated by gamma-knife radiosurgery to
remove a metastasis caused by breast cancer. The lesion
could be a new metastasis or radiation necrosis due to the
radiation therapy. Based on MRI, these two possibilities
A
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AB
Fig. 9a–c MR image with enhanced signal intensity after contrast
administration, which could be caused by the presence of a metastasis
or radiation necrosis, together with an MRSI grid (TE = 20 ms).
aSpectrumofvoxelinenhancingregionwithrathernormalintensitiesof
the major brain metabolites creatine, choline, and NAA and a large lipid
resonance.b Spectrumofcontralateralvoxel in healthytissue showinga
normal pattern of brain metabolite signals. c Spectrum of a metastasis
obtainedfromanother patient. Based uponthe patternofspectruma,th e
diagnosis of radiation necrosis could be made
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123could not be differentiated, but as the MR spectrum showed
rather normal intensities of Cho and NAA in combination
with a high lipid signal, the diagnosis of radiation necrosis
could be made.
Although
1H MRS provides valuable information on
brain tumors, clinicians are not routinely using this
information, mainly because they have no or limited
access to the analysis software and they have no expe-
rience in interpreting the MR spectra. Within the multi-
center project INTERPRET, software has been developed
based on pattern recognition techniques to help clinicians
with the differentiation of brain tumors using information
from
1H MR spectra, mainly obtained from single voxels
located in the tumor (Tate et al. 2006). In the subsequent
multicenter project eTUMOUR (http://www.etumour.net/),
the work by the INTERPRET consortium has been fur-
ther elaborated. In this most recent project, not only data
from SVS spectra are taken into account, but also mul-
tivoxel MRSI data together with information obtained
from high-resolution magic-angle spinning NMR spec-
tra of biopsy material and from analyses by DNA
microarrays. Such multicenter initiatives will certainly
contribute to a more general implementation of MRS in
the clinic.
In addition to
1HM R S ,
31Pa n d
13CM R Sc a na l s ob e
used to investigate brain tumors.
31P MRS has already
been used to investigate pH or ratios of phosphodiesters
and phosphomonoesters in brain tumors in vitro and in
vivo for a long time (Stubbs et al. 1995;M a i n t ze ta l .
2002). Recent technical developments to increase
31P
MRS sensitivity based upon polarization transfer from
1H
to
31P( K l o m pe ta l .2008b) together with the availability
of more MR systems with higher ﬁeld strength may
result in a more frequent use of
31P MRS to follow tumor
treatment response.
13C MRS has been used for several
in vitro studies and in vivo investigations on animal
models. In addition, increased dynamic lactate produc-
tion has recently been shown in vivo in a high-grade
brain tumor by
13C MRS using polarization transfer
(Klomp et al. 2008a) during infusion with
13C-labeled
glucose in a patient (Wijnen et al. 2008). Further,
13C
MRS can play an important role in the detection of hy-
perpolarized compounds. By injection of hyperpolarized
13C-labeled compounds, a technique only recently
introduced in in vivo MRS, the MR signal can be
enhanced on the order of 10,000-fold (Ardenkjaer-Larsen
et al. 2003). This technique has presently—at the time of
writing—only been used in preclinical studies in animals
and not (yet) in humans, but human applications are
expected to be performed in the near future and the
potential in cancer research and biomedicine in general is
very promising.
Conclusions
It has been shown that NMR is not limited to applications
in chemistry, but that MRS is also a valuable tool in the
clinic. With the present availability of MR scanners with
sufﬁciently high ﬁeld strength such as 3T in combination
with optimized pulse sequences and RF coils, the initial
limited sensitivity of in vivo MRS has been much
improved. This, in combination with the unique metabolic
information provided by MRS, ensures that this technique
will be used more and more routinely in the clinic in the
future.
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